PharmaShots’ Key Highlights of Third Quarter 2019

The third quarter of 2019 has ended with major acquisitions in the pharma and biotech industry along with multiple approvals. Starting with the latest acquisition where Biocon Biologics acquires Pfizer's Research Facility for expansion of its R&D footprints with the acceleration of the development of its biosimilars from lab to pilot scale. Previously, Amgen acquired…

BySenior EditorSeptember 7, 20190Comments

TOP 20

Top 20 Life Sciences Deals of 2018 Based on Total Deal Value

Healthcare- pharmaceutical- and biotech companies are gearing up to tap new markets as they look to consolidate their positions after a spate of mergers & acquisitions and licensing partnerships in 2018. The highest valued deal proved to be of Takeda's acquisition of Shire for $57B with the focus on global R&D- its robust and modality-diverse…

ByPrince GiriAugust 23, 20190Comments

INSIGHTS+

Insights+ Key Biosimilars Events of July 2019

Biosimilars are key alternatives for costly Biologics therapies and saving million dollars of patients in multiple diseases. Hence physicians are likely to adopt biosimilars 'a reference product to biologics' which are biologically like biologics. They possess similar therapeutic properties in terms of potency, safety, and efficacy to original biologic products. Our team at PharmaShots have…

BySenior EditorAugust 10, 20190Comments

TOP 20

Top 20 Immunology Companies Based on 2018 Immunology Segment Revenue

The increasing cases of autoimmune disorders such as rheumatoid arthritis are driving the growth of immunology products in the global market. Multiple companies have been focusing on Oncology- Hematology and multiple diseases but due to a drastic increase in the immune disorders- Immunology segment has been widely spared across the globe. In the top 20…

ByPrince GiriAugust 9, 20190Comments

INSIGHTS+

PharmaShots’ Key Highlights of First Quarter 2019

The first quarter of 2019 has marked with major events in the pharma & biotech industries. We have gathered the key highlights of the quarter, which was starting with the blockbuster news, where Celgene had acquired BMS for $74B. Moving to the next news, acquisition of Loxo Oncology for $8B, in addition to Spark Therapeutics…

BySenior EditorAugust 4, 20190Comments

INSIGHTS+

PharmaShots Celebrates Successful Accomplishment of One Year

Shots: Team PharmaShots started their journey on 25 July 2018 and is proudly announcing their completion of one year, with many more to come. PharmaShots has published 1,238 news and articles till date We are grateful to all our subscribers for their affection towards PharmaShots and for subscribing our news alerts. We ensure to put…

BySenior EditorJuly 25, 20190Comments

TOP 20

Top 20 Diagnostics Companies Based On 2018 Revenue

With the era of growing diseases- Diagnostics have played a vital role in diagnosing multiple diseases and disorders. The healthcare system is changing- with a greater focus on value- reducing errors and giving more cost-effective care and treatments. The Diagnostic ledger has not changed much in comparison to 2017. Roche Diagnostics holds to be at…

ByPrince GiriJuly 19, 20190Comments

INSIGHTS+

Insights+: Key Events of ASCO 2019

The American Society of Clinical Oncology (ASCO) is a platform for cancer experts to share views on latest advancement and new approaches in cancer research. In the 55th session of ASCO 2019, 2400+ abstracts were presented. IBM Watson Health was also a part of ASCO 2019 with its advancement in Oncology, Genomics and Patient Monitoring.…

BySenior EditorJuly 6, 20190Comments

INSIGHTS+

Insights+ Key Biosimilars Events of June 2019

Biosimilars are key alternatives for costly Biologics therapies and saving million dollars of patients in multiple diseases. Hence physicians are likely to adopt biosimilars a reference product to biologics which are biologically like biologics. They possess similar therapeutic properties in terms of potency, safety, and efficacy to original biologic products. Our team at PharmaShots have…

BySenior EditorJuly 4, 20190Comments

INSIGHTS+

PharmaShots’ Key Highlights of Second Quarter 2019

The second quarter of 2019 has ended with major acquisitions in pharma and biotech industry. Moving with the latest acquisition of Allergan for $63B by AbbVie focusing on to generate revenue with addition of Allergan's medical aesthetics and ophthalmology portfolio. Prior to that, Pfizer acquired Array Biopharma for $11.4B to expand its oncology portfolio. Some…

BySenior EditorJuly 3, 20190Comments

PharmaShots’ Key Highlights of Third Quarter 2019

Top 20 Life Sciences Deals of 2018 Based on Total Deal Value

Insights+ Key Biosimilars Events of July 2019

Top 20 Immunology Companies Based on 2018 Immunology Segment Revenue

PharmaShots’ Key Highlights of First Quarter 2019

PharmaShots Celebrates Successful Accomplishment of One Year

Top 20 Diagnostics Companies Based On 2018 Revenue

Insights+: Key Events of ASCO 2019

Insights+ Key Biosimilars Events of June 2019

PharmaShots’ Key Highlights of Second Quarter 2019

Contact US

OUR INFORMATION

FOLLW US

FOLLW US

Sign Up to Our Newsletter